Johnson & Johnson launches presbyopia-correcting Tecnis Odyssey IOL in Europe

News
Article

The Tecnis Odyssey, launched in the US in October 2024, is now available in Europe, the Middle East and Canada

A map or globe, with Europe emphasised under a magnifying glass. Concept image for European launch of Johnson and Johnson presbyopia-correcting Tecnis Odyssey IOL. Image credit: ©Pakawadee – stock.adobe.com

The Tecnis Odyssey and Tecnis PureSee IOLs are now both available in Europe, the Middle East, Japan and Canada. Image credit: ©Pakawadee – stock.adobe.com

Johnson & Johnson announced it has launched the Tecnis Odyssey IOL in Europe, the Middle East, and Canada. The Tecnis Odyssey IOL was first launched in the US in October 2024.1,2

The Tecnis Odyssey IOL is a full vision range IOL built on the Tecnis platform which, according to Johnson & Johnson,1 provides two times better contrast in low lighting than PanOptix. The Tecnis Odyssey combines advanced optics and proprietary materials, offering consistently clear, high-contrast vision, according to the company.

Peter Menziuso, company group chairman of Vision at Johnson & Johnson, commented on the launch in a news release from the company, saying, “Tecnis Odyssey IOL is the fastest-growing PC-IOL in the United States, and we are excited to be making it available to more patients around the world. It addresses a significant unmet need for cataract patients seeking greater spectacle independence. Now—together with Tecnis PureSee—Tecnis Odyssey IOL elevates the strength and depth of our global IOL portfolio, meeting the diverse needs of today's aging population.”

Additionally, the company says that the Tecnis Odyssey and its unique freeform diffractive surface were designed to eliminate the gaps between near, intermediate and far distances, and offer continuous, uninterrupted vision at all distances. More than 95% of patients were satisfied with both reading on a smartphone/tablet and distance vision.

Johnson & Johnson’s portfolio of advanced presbyopia correcting IOLs available in Europe, the Middle East, Canada and Japan now includes both the Tecnis Odyssey IOL and the Tecnis PureSee IOL.

References:

  1. Johnson & Johnson launches new TECNIS Odyssey next-generation intraocular lens in Europe, the Middle East, and Canada offering cataract patients precise vision at every distance in any lighting. June 17, 2025. Accessed June 17, 2025. https://www.prnewswire.com/news-releases/johnson--johnson-launches-new-tecnis-odyssey-next-generation-intraocular-lens-in-europe-the-middle-east-and-canada-offering-cataract-patients-precise-vision-at-every-distance-in-any-lighting1-6--302483215.html
  2. Harp MD. Johnson & Johnson launches TECNIS Odyssey IOL in US. October 1, 2024. Accessed June 17, 2025. https://www.ophthalmologytimes.com/view/johnson-johnson-launches-tecnis-odyssey-iol-in-us

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
Related Content
© 2025 MJH Life Sciences

All rights reserved.